Histone methylation is carried out by methyltransferases and demethylases, two classes of enzymes. While methyltransferases are in charge of creating methylation patterns, demethylases have the ability to remove methyl groups from proteins other than histones. Histone demethylases interact with methylated sites on non-histone proteins, such as p53, in addition to targeting methylated sites on histone tails.
Due to their regulatory functions in chromatin organization and their close ties to diseases like cancer and mental disorders, histone lysine demethylases (KDMs) are of interest as drug targets.
Demethylase JMJD1A, also known as KDM3A, eliminates methyl from histone lysine H3K9. It is crucial for many cellular functions, such as spermatogenesis, energy metabolism, stem cell control, and gender expression.
A histone demethylase known as Jumonji domain-containing 3 (Jmjd3) has been discovered, and it specifically catalyzes the removal of methylation from H3K27me3.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V56069 | MC2652 | 2771425-46-6 | MC2652 (compound 1a) is a potent LSD1 inhibitor. |
|
V0375 | ML324 (CID44143209) | 1222800-79-4 | ML324 (also known as CID-44143209) is a cell-permeable and selective inhibitor of jumonji histone demethylase (JMJD2) with antiviral activity. |
|
V76737 | MY-943 | MY-943 is a potent inhibitor of tubulin polymerization and LSD1 with anti-cancer activity. | |
|
V41137 | Namoline | 342795-11-3 | Namoline, a γ-pyrone, is a selective, reversible inhibitor of lysine-specific demethylase 1 (LSD1) with IC50 of 51 μM in an HRP-conjugating enzyme assay. |
|
V80906 | NCD38 TFA | NCD38 TFA is a selective inhibitor of LSD1. | |
|
V86100 | NCL1 | 1196119-03-5 | |
|
V0370 | OG-L002 | 1357302-64-7 | OG-L002 (OG-L-002) is a pecific inhibitor of LSD-1 [lysine (K)-specific demethylase 1A] with potential antiviral activity. |
|
V88876 | P3FI-63 | 931596-95-1 | P3FI-63 is a KDM3B inhibitor with IC50 of 7 μM. |
|
V27126 | PBIT | 2514-30-9 | PBIT is a specific Jumonji/AT enriched interacting domain 1 (JARID1) inhibitor. |
|
V15540 | Pulrodemstat (CC90011) | 1821307-10-1 | Pulrodemstat (formerly CC-90011; LSD1-IN-7; CC90011) is a novel, highly potent, reversible and orally bioavailable inhibitor of lysine specific demethylase-1 (LSD1) with anticancer activity. |
|
V40117 | Pulrodemstat (CC90011) besylate | 2097523-60-7 | Pulrodemstat besylate (formerly CC-90011 besylate; LSD1-IN-7), the besylate salt of CC-90011 (LSD1-IN7; CC90011), is a highly potent and orally bioavailable inhibitor of lysine specific demethylase-1 (LSD1) with potential anticancer activity. |
|
V52293 | Pulrodemstat Methylbenzenesulfonate (CC-90011 Methylbenzenesulfonate; LSD1-IN-7 Methylbenzenesulfonate) | 2097523-57-2 | CC-90011 Methylbenzenesulfonate is a specific, reversible and orally bioactive lysine-specific demethylase-1 (LSD1) inhibitor (antagonist) with IC50 of 0.25 nM. |
|
V56071 | S1427 | 2447061-40-5 | S1427 is a tranylcypromine-derived LSD1 inhibitor (antagonist) with IC50 of 390 nM and a Ki of 80 nM. |
|
V37863 | S2116 | 2262489-89-2 | S2116 is an N-alkylated trans-cyclopropylamine (TCP) analogue and a potent lysine-specific demethylase 1 (LSD1) inhibitor. |
|
V37842 | S2157 | 2262488-39-9 | S2157 is an N-alkylated trans-cyclopropylamine (TCP) analogue and a potent lysine-specific demethylase 1 (LSD1) inhibitor. |
|
V106270 | S9-CMC1 TFA | S9-CMC1 TFA is a covalent peptide lysine-specific demethylase 1 (LSD1) inhibitor with IC50 of 2.53 μM. | |
|
V3833 | Seclidemstat | 1423715-37-0 | Seclidemstat (formerly also known as SP-2577; SP2577) is a novel, potent small molecule inhibitor of epigenetic enzyme LSD1 (lysine-specific demethylase 1) with anticancer activity. |
|
V37130 | Seclidemstat mesylate (SP-2577 mesylate) | 2044953-70-8 | Seclidemstat (SP-2577) mesylate is a potent, noncompetitive, reversible inhibitor of KDM1A (LSD1) (Ki=31 nM, IC50). |
|
V76508 | SKLB325 | 66680-03-3 | SKLB325 is a JMJD6 inhibitor (antagonist) with a binding affinity (KD) value of 0.755 μM and IC50 of 0.7797 μM. |
|
V0373 | SP2509 (HCI-2509) | 1423715-09-6 | SP2509 (HCI2509) is a novel, potent and selective histone demethylase LSD1(KDM1A) antagonistwith antineoplastic activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
